IGC IGC Pharma, Inc.
Pharmaceutical Preparations · NYSE · SEC CIK 1326205 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY13.9%
TTM net income YoY-25.8%
TTM EPS YoY7.4%
Revenue 3-yr CAGR-2.1%
Net income 3-yr CAGR—
Margins
Gross margin16.5%
Operating margin-802.7%
Net margin-643.7%
FCF margin-415.2%
EBITDA margin-786.5%
Returns
ROE-111.1%
ROA-83.3%
ROIC (approx.)-120.6%
Asset turnover0.13x
Leverage & solvency
Liabilities / assets33.2%
Debt / equity0.00x
Current ratio0.42x
Interest coverage-1,685.67x
Cash quality & payout
Operating cash flow / net income0.64x
Accruals ratio-29.8%
Payout ratio—
Capex / revenue1.4%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-03-31 | FY20242024-03-31 |
|---|---|---|
| Income statement | ||
| Revenue | $1.27M | $1.34M |
| Cost of revenue | $652,000 | $612,000 |
| Gross profit | $619,000 | $733,000 |
| R&D expense | $3.65M | $3.77M |
| SG&A expense | $4.41M | $6.76M |
| Operating income | -$7.45M | -$9.80M |
| Interest expense | $5,000 | $5,000 |
| Pretax income | -$7.12M | -$13.00M |
| Income tax | $0 | $0 |
| Net income | -$7.12M | -$13.00M |
| EBITDA | -$6.83M | -$9.16M |
| EPS (basic) | -0.09 | -0.22 |
| EPS (diluted) | -0.09 | -0.22 |
| Weighted avg. shares (diluted) | 76.52M | 58.84M |
| Balance sheet | ||
| Cash & equivalents | $405,000 | $1.20M |
| Short-term investments | $0 | $0 |
| Receivables | $34,000 | $39,000 |
| Inventory | $1.36M | $1.54M |
| Current assets | $2.90M | $3.71M |
| PP&E, net | $3.22M | $3.69M |
| Intangibles | $1.85M | $1.62M |
| Total assets | $8.75M | $9.90M |
| Current liabilities | $2.26M | $2.34M |
| Short-term debt | $3,000 | $3,000 |
| Long-term debt | $134,000 | $137,000 |
| Total debt | $137,000 | $140,000 |
| Total liabilities | $2.42M | $2.58M |
| Shareholders' equity | $6.33M | $7.32M |
| Net debt | -$268,000 | -$1.06M |
| Shares outstanding | 80.88M | 66.69M |
| Cash flow statement | ||
| Operating cash flow | -$4.79M | -$5.20M |
| Capital expenditure | $112,000 | $138,000 |
| Free cash flow | -$4.91M | -$5.34M |
| Investing cash flow | -$442,000 | -$317,000 |
| Financing cash flow | $4.45M | $3.52M |
| Depreciation & amortization | $618,000 | $637,000 |
| Stock-based compensation | $1.64M | $1.77M |
Free plan shows the latest 2 periods; Pro shows all 15 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.